Clinical entity of cytomegalovirus disease in patients with malignant lymphoma on bendamustine therapy: a single-institution experience

References

• Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010;116(1):106–114.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210.
   PubMed Web of Science ®Google Scholar
• Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–2952.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018;36(23):2395–2404.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155–165.
   PubMed Web of Science ®Google Scholar
• Ohmoto A, Fuji S. Infection profiles of different chemotherapy regimens and the clinical feasibility of antimicrobial prophylaxis in patients with DLBCL. Blood Rev. 2021;46:100738.
   PubMed Web of Science ®Google Scholar
• Fung M, Jacobsen E, Freedman A, et al. Increased risk of infectious complications in older patients with indolent non-Hodgkin lymphoma exposed to bendamustine. Clin Infect Dis. 2019;68(2):247–255.
   PubMed Web of Science ®Google Scholar
• Lim SH, Pathapati S, Langevin J, et al. Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine. Ann Hematol. 2012;91(4):643–644.
   PubMed Web of Science ®Google Scholar
• Cona A, Tesoro D, Chiamenti M, et al. Disseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating B- and T-cell subsets. BMC Infect Dis. 2019;19(1):881.
   PubMed Web of Science ®Google Scholar
• Hosoda T, Yokoyama A, Yoneda M, et al. Bendamustine can severely impair T-cell immunity against cytomegalovirus. Leuk Lymphoma. 2013;54(6):1327–1328.
   PubMed Web of Science ®Google Scholar
• Magliano G, Cuccaro A, d‘Alo’ F, et al. Severe CMV infection after chemo-immunotherapy with dose-reduced bendamustine and rituximab in a mantle cell lymphoma old patient. Mediterr J Hematol Infect Dis. 2021;13(1):e2021054.
   PubMedGoogle Scholar
• Yamasaki S, Kohno K, Kadowaki M, et al. Cytomegalovirus retinitis in relapsed or refractory low-grade B cell lymphoma patients treated with bendamustine. Ann Hematol. 2017;96(7):1215–1217.
   PubMed Web of Science ®Google Scholar
• Singhania SVK, Parikh P, Goyle S. CMV pneumonitis following bendamustine containing chemotherapy. J Assoc Physicians India. 2017;65(9):92–93.
   PubMedGoogle Scholar
• Murayama K, Kiguchi T, Izutsu K, et al. Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma. Ann Hematol. 2022;101(5):979–989.
   PubMed Web of Science ®Google Scholar
• Pezzullo L, Giudice V, Serio B, et al. Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens. Open Med (Wars). 2021;16(1):672–682.
   PubMedGoogle Scholar
• Matsumoto Y, Kobayashi T, Shimura Y, et al. Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study. Int J Hematol. 2019;110(1):77–85.
   PubMed Web of Science ®Google Scholar
• Hasegawa T, Aisa Y, Shimazaki K, et al. Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma. Ann Hematol. 2015;94(3):515–517.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64(1):87–91.
   PubMed Web of Science ®Google Scholar
• Gondo H, Minematsu T, Harada M, et al. Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation. Br J Haematol. 1994;86(1):130–137.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.
   PubMed Web of Science ®Google Scholar
• Isono N, Imai Y, Watanabe A, et al. Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine. Leuk Lymphoma. 2016;57(9):2204–2207.
   PubMed Web of Science ®Google Scholar
• Chiba A, Nakamura F, Nakazaki K, et al. Cytomegalovirus antigenemia and end-organ disease in Japanese patients treated with bendamustine. Leuk Lymphoma. 2018;59(3):749–751.
   PubMed Web of Science ®Google Scholar
• Linhares MI, de Andrade GP, Tateno S, et al. Prevalence of cytomegalovirus antibodies in Brazilian and Japanese populations in the North-east of Brazil. Microbiol Immunol. 1989;33(11):975–980.
   PubMed Web of Science ®Google Scholar
• Inde Y, Yamaguchi S, Kamoi S, et al. Transition of cytomegalovirus seropositivity in Japanese puerperal women. J Obstet Gynaecol Res. 2010;36(3):488–494.
   PubMed Web of Science ®Google Scholar
• Shigemi D, Yamaguchi S, Otsuka T, et al. Seroprevalence of cytomegalovirus IgG antibodies among pregnant women in Japan from 2009–2014. Am J Infect Control. 2015;43(11):1218–1221.
   PubMed Web of Science ®Google Scholar
• Carrasco E, Gómez de Las Heras MM, Gabandé-Rodríguez E, et al. The role of T cells in age-related diseases. Nat Rev Immunol. 2022;22(2):97–111.
   PubMed Web of Science ®Google Scholar
• Palmer DB. The effect of age on thymic function. Front Immunol. 2013;4:316.
   PubMed Web of Science ®Google Scholar